Objectives: Heterogeneously resistant vancomycin-intermediate coagulase-negative staphylococci (hVICoNS) are emerging pathogens causing central-line-associated bloodstream infections (CLABSIs) in neonatal intensive care unit (NICU) patients. Given the burden of disease associated with CLABSI and the current lack of therapeutic guidelines, we aimed to compare the effectiveness of linezolid versus vancomycin used as the definitive antibiotic therapy for hVICoNS CLABSI.
Introduction
Once considered mere contaminants, CoNS have now become widely recognized as predominant pathogens of central-lineassociated bloodstream infections (CLABSIs) in the neonatal intensive care unit (NICU). 1 CLABSI remains a major nosocomial complication in NICU patients, particularly in preterm infants with very low (VLBW) and extremely low birth weight (ELBW) due to their immune immaturity and frequent invasive procedures.
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By 3 days of life, 10% of VLBW infants will develop CoNS sepsis, while 50% of late-onset bloodstream infections (BSIs) are caused by CoNS. 1 In a recent NICU-based study, the mortality rate for infants with definite CoNS bacteraemia was 10%. 2 CoNS CLABSI have also been associated with intraventricular haemorrhage, retinopathy of prematurity, bronchopulmonary dysplasia and neurodevelopmental impairment. [3] [4] [5] [6] Vancomycin heterogeneity or heteroresistance is defined as a bacterial strain that appears susceptible to vancomycin but includes a subpopulation with a vancomycin MIC 8 mg/L. 7 Although mainly described in Staphylococcus aureus, strains of CoNS with mixed susceptibility to vancomycin, or heterogeneously vancomycin-intermediate coagulase-negative staphylococci (hVICoNS), have also been described. [8] [9] [10] Routine laboratory techniques, such as the disc diffusion method, fail to detect heteroresistance to vancomycin in staphylococci; the gold standard is thought to be the population analysis profile-area under the curve (PAP-AUC) test, 11 which is only available in research laboratories and quite time-consuming. 12 The Etest Glycopeptide Resistance Detection (GRD) has been described as a useful and easily accessible method for the detection of heteroresistance in S. aureus in clinical laboratories, with enhanced detection using enriched media, prolonged incubation, and testing for both vancomycin and teicoplanin when performing the Etest GRD. 11 The clinical significance of heteroresistance in CoNS strains remains unclear, however.
Given near-universal methicillin resistance, vancomycin has become the treatment of choice for CoNS infections. Since the first report of decreased CoNS susceptibility to vancomycin was published in 1999, 13 many more have followed, 8, 9, 13 but to date there are still no official guidelines on the treatment of such infections. Linezolid, an oxazolidinone, is an alternative to vancomycin in the treatment of resistant staphylococcal infections. Since December 2002, the US FDA has approved linezolid for use in infants and children, and although it is currently an off-label therapeutic option in the neonatal population for CoNS BSIs, its successful use has been reported in premature infants. [14] [15] [16] To our knowledge, no study to date has assessed the clinical effectiveness of linezolid versus vancomycin in hVICoNS CLABSI in NICU patients. We thus compared the effectiveness of linezolid versus vancomycin used as the definitive antibiotic therapy for hVICoNS CLABSI in terms of duration of infection, recurrence and mortality.
Materials and methods

Study design and population
We conducted a retrospective cohort study from 1 April 2009 to 30 March 2014 in a tertiary care centre level III NICU in Montreal. The NICU has 65 beds with 1100 admissions yearly, of which 125 are ELBW infants.
Cases were identified through a prospective database, created by our local infection prevention and control team. During the study period, there was an important increase in rates of hVICoNS infections, leading to enhanced surveillance and implementation of rigorous preventive strategies. A multidisciplinary clinical protocol created by medical microbiologists, local infectious diseases specialists, neonatologists and hospital pharmacists was introduced in June 2012, recommending linezolid as a first-line agent for: (i) NICU infants with Gram-positive cocci on a single blood culture AND thrombocytopenia OR lack of improvement on vancomycin; and (ii) NICU infants with identified CoNS from a blood culture. We established treatment groups based on the predominantly administered antibiotic. Therefore, patients initially treated with vancomycin and then switched to linezolid treatment in 24 h were considered treated with linezolid and vice versa.
Inclusion criteria
Included were all NICU patients with: (i) at least one positive blood culture for hVICoNS AND (ii) a central line in place for at least 48 h prior to a first positive blood culture AND (iii) who were treated with either linezolid or vancomycin.
Exclusion criteria
Patients who developed CLABSI due to CoNS without heteroresistance to vancomycin were excluded. Additionally, patients with confirmed hVICoNS but who were administered antimicrobials other than linezolid or vancomycin (e.g. cloxacillin) were excluded. We also excluded patients who were transferred to other hospitals during treatment, as we could not assess outcomes such as recurrence or mortality. Patients who could not be assigned to either antibiotic treatment because they were treated for an equal number of days on both antimicrobials were excluded from the analysis.
Ethics
Local research ethics board approval was obtained (13-370-PED/OCC213-498).
Data collection
Data were obtained from electronic and paper medical records and entered into a standardized case report form. Collected data included patient demographics, underlying medical conditions, central venous catheter (CVC) characteristics, microbiological data, antibiotic dose and plasma/ serum levels, CLABSI complications and clinical outcomes. Collected data were entered in a de-identified database. A random audit of five charts was performed to ensure accuracy and data quality. Each patient was followed until discharge from hospital or death.
Variable definitions CLABSI
CLABSI was defined using the former National Healthcare Safety Network (NHSN) criteria. 17 In summary, patients needed to have a CVC at the time of CLABSI onset or in the previous 48 h with CoNS isolated from one or more blood cultures, not associated with a primary infection site elsewhere, and for whom the treating physician initiated treatment. The local infection prevention and control team had elected to keep this definition for comparison purposes and because neonatologists felt it was unreasonable to obtain two blood cultures before initiating antimicrobials in premature infants.
Outcomes
The primary outcome was CLABSI duration, defined as the number of days between the first positive and the first negative blood culture for a given episode (continuous variable). Secondary outcomes (categorical variables) included CLABSI recurrence defined as: (i) early CLABSI recurrence (new positive blood culture with hVICoNS 2 weeks after first negative blood culture from previous episode); or (ii) late CLABSI recurrence (new positive blood culture with hVICoNS .2 weeks after the first negative blood culture from previous episode); and (iii) in-hospital mortality (at 30 days), defined as all-cause mortality occurring during NICU stay.
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Definitive antibiotic therapy
Definitive antibiotic therapy was defined as the intravenous antibiotic used for most consecutive days after a positive blood culture, for at least 3 days.
In patients who survived, antibiotic therapy end date was the last consecutive day that linezolid or vancomycin was administered. Intravenous (iv) or oral linezolid was administered at 10 mg/kg/dose q12h for infants 34 weeks of gestational age (GA) between 0 and 7 days of life; q8h after 7 days of life in patients 34 weeks of GA and in all patients 35 weeks of GA. 18 Target linezolid plasma concentration levels were above the pathogen's MIC, i.e. .2 mg/L and AUC 0-24 /MIC ratio .80-120. 19 For patients 29 weeks of GA, initial iv vancomycin was administered at 10 mg/kg/dose q12h between 0 and 14 days and q8h after 14 days of life. In patients 30-36 weeks of GA, it was given q8h between 0 and 14 days of life and q6h after 14 days of life. In patients 37 weeks of GA, it was administered q8h between 0 and 7 days of life and q6h after 7 days of life. In the context of renal failure, dosing interval was prolonged (from q12h to q18h; from q8h to q12h, and from q6h to q8h). Dosing was then adjusted according to therapeutic drug monitoring targeting a steady-state serum trough level of 10-15 mg/L. 20 
Microbiological detection and identification of organisms
Blood cultures were considered positive based on the VersaTREK automated microbial growth detection system (Thermo Fisher Scientific, Oakwood Village, OH) and identified by the automated VITEK 2 system (bioMérieux, Inc., Hazelwood, MO).
Antimicrobial susceptibility testing
All antimicrobial susceptibility testing was based on clinical breakpoints following CLSI criteria. 21 Vancomycin heteroresistance was determined using both the Etest GRD and Etest macromethod (bioMérieux), which were performed on all CoNS strains identified from positive blood cultures of patients with CLABSI. The Etest GRD was performed according to the manufacturer's instructions (AB Biodisk) using a double-sided predefined gradient of vancomycin and teicoplanin. A 0.5 McFarland standard inoculum was prepared and swabbed onto Mueller-Hinton agar (MHA) with 5% sheep blood (MHB) (BBL, Becton Dickinson and Company). A GRD strip consisting of a doublesided gradient with vancomycin and teicoplanin was then applied to the MHB plate and a standard vancomycin Etest was applied to the MHA plate. The inhibition zone was read at 24 and 48 h after incubation at 35 C. The test isolate was considered heterogeneously intermediate to vancomycin if the Etest GRD strip result was 8 mg/L for either vancomycin or teicoplanin and the standard vancomycin Etest MIC was 4 mg/L, based on definitions previously used for S. aureus. 22 The macrodilution method Etest was performed as previously described. 23 
Statistical analysis
We used descriptive statistics, v 2 tests for categorical variables and Student's t-tests for continuous variables. We used multivariable regression models to compare outcomes of patients treated with linezolid and vancomycin (proportional hazards regression for CLABSI duration and logistic regression for other outcomes). Models were adjusted using a continuous propensity score including extreme values, to include as many observations as possible (highest power, n " 89); however, alternative models were also tested (quintiles versus continuous score and inclusion versus exclusion of extreme values) but made little difference. To build the propensity score (to determine patients' likelihood of receiving one antimicrobial more than another), patients' characteristics were compared using the v 2 test or Student's t-test. All variables with a P value ,0.2 or that were deemed important (e.g. birth weight category, neurological comorbidities) were included in the propensity score.
The following variables were included in the final propensity score: abdominal surgery, gastrointestinal condition (acquired or congenital), birth weight category, sex, any respiratory condition including invasive mechanical ventilation or oxygen need, any neurological condition, patent ductus arteriosus and renal failure. Because the value for platelets was recorded in the 2 weeks around CLABSI onset and thus could have been a consequence of linezolid use rather than an indication of CLABSI severity, and because it was not statistically different between the two treatment groups, it was not included in the propensity score. All reported 95% CIs were two-sided. All statistical analyses were performed using SAS v. 9.2 (SAS Institute Inc., Cary, NC, USA) and STATA 12.0.
Results
Of 111 infants identified, 22 were excluded: 9 did not have a CVC, 3 had a CLABSI caused by a pathogen other than hVICoNS, 1 was transferred to another medical facility, 5 were treated with antimicrobials other than linezolid or vancomycin and 2 died before any treatment was initiated. For the remaining two patients, there was no clear predominance of one antibiotic over the other. In total, 89 patients were included; 33 (37.1%) were treated with linezolid and 56 (62.9%) with vancomycin. Table 1 details infants' demographic characteristics stratified by their definitive antibiotic regimen, as well as the underlying medical conditions preceding hVICoNS CLABSI. CLABSI characteristics are detailed in Table 2 . Species included Staphylococcus epidermidis (n " 86), Staphylococcus warneri (n " 2) and Staphylococcus capitis (n " 1). Overall, 76 infants (85.4%) had only one positive blood culture at CLABSI diagnosis, 11 (12.4%) had two and 2 (2.2%) had three. Eighty-five infants (96%) had at least one documented negative blood culture. Four patients died before having a repeated negative blood culture (two were treated with vancomycin and died at 5 and 0 days after the last positive blood culture; two were treated with linezolid and died at 3 and 0 days after the last positive blood culture). At baseline, there was no difference in the proportion of infants in each treatment group for the following variables: antibiotics at birth or in the 48 h before CLABSI onset, haemodynamic instability, increase in ventilation parameters, neutropenia, or intraventricular haemorrhage (data not shown). Overall, 63.6% (n " 21) and 51.8% (n " 29) of infants in the linezolid and vancomycin treatment groups, respectively, had a platelet count ,50%10 9 /L during the 2 weeks around CLABSI onset (P " 0.28).
All infants treated with linezolid started with the iv formulation; 6/33 (18%) were switched to oral therapy when iv treatment was no longer possible. Linezolid plasma concentrations were done in 21/33 patients (63.6%) and 20/21 (95.2%) were considered therapeutic. Vancomycin trough serum concentration was determined in 54/56 patients (96.4%) and was therapeutic in 38/54 (70.4%), with a mean delay of 2 days needed for dosing adjustments. Univariate analysis showed no significant difference in the general clinical acuteness of patients in the two treatment groups, except that more patients treated with vancomycin had required intubation and mechanical ventilation before CLABSI (Table 1) . There was no difference in terms of other patient characteristics, centralline characteristics or CLABSI diagnostic methods. Mean age at CLABSI was similar (20.8+14.1 versus 20.4+19.9 days). Mean length of stay in the NICU was 90.6+62.7 days in the linezolid group versus 119.7+64.5 days in the vancomycin group (P " 0.043).
Clinical outcomes
Mean duration of CLABSI was 4.6 days in the linezolid group compared with 3.6 days in the vancomycin group (P " 0.11) ( Table 3) .
Recurrence
Early recurrence occurred in 1/33 patients (3.0%) treated with linezolid versus 4/56 patients (7.1%) treated with vancomycin (P " 0.42). Late recurrence did not occur in any patient treated with linezolid and occurred in 8/56 patients (14.3%) treated with vancomycin (P , 0.02) ( Table 3) .
Mortality
Overall, 25 infants died (28.1%), including 9/33 patients (27.3%) treated with linezolid and 16/56 patients (28.6%) treated with vancomycin (Table 3 ). There was no statistically significant difference in the 30 day all-cause mortality between the two groups. Patients were younger at the time of death in the linezolid versus the vancomycin group: median age 29 versus 42 days (P " 0.038). The median interval between CLABSI diagnosis and time of death was 9 days (range 4-26) in patients treated with linezolid versus 10 days (range 0-21) in patients treated with vancomycin (P " 0.570).
Multivariate analysis, adjusted using propensity scores as previously defined, showed no statistical difference for any of the outcomes (Table 4) . Linezolid had an HR of 0.78 (95% CI 0.48-1.27) for CLABSI duration, an OR of 0.23 (95% CI 0.02-2.56) for early recurrence and an OR of 0.9 (95% CI 0.3-2.67) for mortality, in comparison with vancomycin. The model for late recurrence was very unstable, given the small number of events.
Discussion
To our knowledge, this study is the first to compare linezolid and vancomycin as definitive treatment of hVICoNS CLABSI in NICU patients. This analysis, adjusted with a propensity score, did not find any significant statistical difference in hVICoNS CLABSI duration (5 versus 4 days when treated with linezolid and vancomycin, respectively), recurrence or all-cause mortality, suggesting that linezolid is neither superior nor inferior to vancomycin for the treatment of hVICoNS CLABSIs. This study came about after a series of patients presented with clinical symptoms of sepsis and positive blood cultures for CoNS, with evidence of increasing MICs of vancomycin, using Etest GRD to confirm the isolates' hVICoNS status. 24 Although CoNS strains contained subpopulations of cells with reduced susceptibility to vancomycin, which could have an impact on clinical presentation and treatment response, 9 the actual clinical significance of CoNS heteroresistance to vancomycin in vivo has yet to be fully established.
In their study, Deville et al. 25 reported that drug-related adverse events, including renal impairment and oral/skin candidiasis, were less frequent with linezolid versus vancomycin (32% versus 12%; P " 0.06). They also reported that thrombocytopenia did not occur more frequently with linezolid than vancomycin (5% versus 0%; P " 0.34) and seemed to occur with longer duration of therapy 25 An open-label trial of linezolid versus vancomycin in 63 infants showed no significant differences in the occurrence of thrombocytopenia (linezolid 1.9% versus vancomycin 0%; P " 0.17) or other drug-related haematological events, with treatment duration ,14 days. 26 A post hoc analysis of the trial by Wilcox et al. 27 describing empirical treatment of CLABSI using linezolid reported a non-significant increase in mortality in patients with Gram-negative bacteraemia and a significant increase in mortality in patients with negative blood cultures in the linezolid arm. Based on these data, recently published IDSA guidelines for CLABSI management recommended against linezolid use as empirical therapy. 28 On the other hand, a recent study by Ternavasiode la Vega et al. 29 aiming to evaluate the potential impact of linezolid versus glycopeptides on 30 day mortality rate in patients with Gram-negative bacteraemia showed that empirical use of linezolid was not associated with higher mortality.
There were limitations to our study. First, infants did not have daily blood cultures, and therefore the exact duration of bacteraemia was impossible to establish. Moreover, there was often a single positive blood culture before antimicrobials were initiated, as is frequently seen in the NICU population. Based on this, we cannot exclude that some of these positive blood cultures represented contamination; however, the chart review revealed symptoms and signs of sepsis for each patient. The lack of statistical difference may be attributable to insufficient power due to our small sample size. However, given the change in local clinical guidelines, extending the duration of the study would not allow more infants to be treated with vancomycin. It is also possible that because only a minority of bacteria within each hVICoNS isolate are vancomycin intermediate, iv vancomycin therapy probably retains equal clinical effectiveness compared with linezolid for pathogen eradication. The main reason for therapeutic shift from vancomycin to linezolid was to avoid overuse of vancomycin, potentially leading to selective pressure, which has been described to promote precursor heterogeneous vancomycinintermediate S. aureus (hVISA) to vancomycin-intermediate S. aureus through ongoing antibiotic exposure. 30 It is, however, unclear whether such extrapolation from S. aureus can be extended to CoNS. In terms of efficacy, studies have demonstrated that linezolid can achieve pathogen eradication rates equal to that of vancomycin in neonates with Gram-positive infections (of which 80% were staphylococci). 25 Study limitations also included its retrospective nature, for which we tried to mitigate the risk of bias by rigorous and systematic data collection followed by regular data verification. We anticipated historical bias, based on a change in overall clinical management and treatment of patients with hVICoNS CLABSI at our hospital over a 6 year period. We adjusted for baseline patient characteristics using a propensity score in a multivariable model analysis aiming to make both groups as comparable as possible, despite confounders. We excluded patients who developed CLABSI due to hVICoNS who were treated with antimicrobials other than vancomycin or linezolid, and neonates who were transferred to other hospitals during treatment, as we could not assess their end clinical outcomes.
This study is one of the largest series of hVICoNS CLABSIs in a tertiary care NICU described in the literature thus far. Furthermore, adding more patients to our series would only result in more patients being added to the linezolid group, as this is the current local clinical guideline for the treatment of hVICoNS. We believe that the absence of variation in effect measured through different adjustments of the propensity score suggests that our results are relatively robust. Finally, the Etest macromethod and the Etest GRD have only been validated for S. aureus, where resistance may be mediated by biological mechanisms that are different from those in CoNS. The model for late recurrence was very unstable and did not converge, given the small number of events.
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In conclusion, this study did not find any obvious difference in the effectiveness of linezolid versus vancomycin when used as the definitive treatment of NICU patients with hVICoNS CLABSI, after adjusting for potential confounders. The use of linezolid to decrease antimicrobial pressure on CoNS should be weighed against the absence of long-term safety data when used in infants. More studies are needed to support empirical treatment of neonates with linezolid, especially for longer treatment courses; vancomycin remains an adequate definitive antimicrobial treatment based on clinical effectiveness.
